Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer-Reference-Cited by-同舟云学术

Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer

Published:2002-06 Issue:11 Volume:86 Page:1677-1683
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Cunningham D,Falk S,Jackson D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6600204.pdf

Reference23 articles.

1. British National Formulary (March 1999) Number 35

2. Cancer Research Campaign (1995) Factsheets 3.2–3.3. UK Cancer Statistics London: CRC

3. Conti JA, Kemeny NE, Saltz LB et al (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 3 709–715

4. Creemers GJ, Lund B, Verweij J (1994) Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 20: 73–96

5. Cunningham D, Pyrhönen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413–1418

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A 5-fluorouracil–kaempferol drug–drug cocrystal: a ternary phase diagram, characterization and property evaluation;CrystEngComm;2020

2. Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity;Pharmacology & Therapeutics;2019-07

3. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion;Health Technology Assessment;2015-11

4. Cost–utility analysis of operative versus non-operative treatment for colorectal liver metastases;British Journal of Surgery;2015-01-26

5. Cost-minimization Analysis of S-1 Plus Irinotecan (IRIS) versus Oxaliplatin or Irinotecan Plus Fluorouracil and Folinic Acid (mFOLFOX6 or FOLFIRI) in Patients with Advanced Colorectal Cancer;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2015